复方新诺明联合二线药物治疗耐多药结核病的临床疗效分析

Clinical efficacy of compound sulfamethoxazole combined with second-line drugs in treatment of MDR-TB

目的评价复方新诺明(SMZ.Co)对耐多药结核病(MDR-TB)的抗结核疗效。方法收集该院2014年3月1日至2016年12月31日MDR-TB患者85例,分A、B、C 3组。C组行常规二线抗结核治疗,在此基础上,A组增加0.96g SMZ.Co,B组增加0.48g SMZ.Co,比较3组患者的治疗效果(咳嗽、咳痰情况、痰菌转阴率、影像学检查及治疗转归情况等)。结果持续治疗6个月后,与C组相比,A、B组患者咳嗽、咳痰率明显下降,差异有统计学意义(P<0.05),但痰菌阴转率、病灶、空洞的变化与治疗转归率比较差异无统计学意义(P>0.05)。结论抗结核治疗方案中联合使用SMZ.Co可有效减轻MDR-TB患者咳嗽、咳痰等症状。

Objective To investigate the effect of compound sulfamethoxazole（SMZ. Co） combined with second-line drugs in the treatment of multiple drug-resistant tuberculosis（MDR-TB）. Methods Eighty-five cases of MDR-TB collected in this hospital from March 2014 to December 2016 were divided into the group A, B and C group. The C group underwent the conventional secondline anti-TB treatment,on this basis the group A and B were additionally added with 0. 96 g and 0.48 g SMZ. Co respectively. The clinical curative effects（such as cough, phlegm, sputum bacterial negative conversion rate and X-rays） were compared among the three groups. Results Compared with C group,the cough and phlegm rates after continuous treatment for six months in the group A and B treated by combined use of SMZ. Co were significantly decreased, the difference was statistically significant（P〈0.05）, while the sputum bacterial negative conversion rate,change of lesion focus and cavity, and treatment outcome rate had no statistical difference（P〉0.05）. Conclusion The application of SMZ. Co combined with second-line drugs in the treatment of MDR-TB could effectively relieve the symptom of cough and phlegm.